Clin2
NCT07065357Possibly a fitEnrolling by invitation

A study on a diabetes drug for metabolic syndrome

Metabolic Syndrome

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
160 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You must be 18 to 84 years old.
  • You must have metabolic syndrome (large waist size plus two other issues like high blood sugar, high blood pressure, or abnormal cholesterol).
  • You must not be taking any diabetes medications.
  • Your blood sugar must not be too high (fasting glucose under 7.0 mmol/L or HbA1c under 6.5%).
  • You must not have type 1 diabetes.
  • You must not have kidney problems (low filtration rate).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05972564Recruiting· Phase 1/Phase 2
SGLT2 drug trial for belly fat inflammation before weight-loss surgery

This early-phase trial tests whether an SGLT2 drug can reduce inflammation in belly fat and improve blood vessel function. It may help people with metabolic syndrome prepare for (and potentially benefit around) planned gastric bypass or sleeve surgery.

Nashville, Tennessee
NCT05905965Recruiting· Phase 3
Higher versus standard empagliflozin dose for metabolic syndrome

This trial tests whether a higher dose of empagliflozin works better than the standard dose to treat metabolic syndrome. It may help improve blood sugar and cholesterol-related risk factors in people who meet the trial’s criteria.

Bydgoszcz, Cuiavian-Pomeranian
NCT07336797Recruiting· Phase 2
Empagliflozin for weight and metabolism in HIV

This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.

Cairo
NCT06507657Recruiting· Early Phase 1
Empagliflozin for heart health in older adults

This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.

Minneapolis, Minnesota
NCT07053319Recruiting· Phase 1
Study of diabetes drugs and ketones

This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.

San Antonio, Texas
NCT07311551Not yet recruiting· Phase 4
Comparing two diabetes drugs for weight management

This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.

Hear when a new Metabolic Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.